CellPryme-M question, page-21

Forgetting third party application for this tech just for a moment. We need to remember that this will be used, with OmniCar for trials against AML and GBM. I think they hit arms next year.

Data from these trials can be used for safety etc for further applications. So we just need to sit back and have some patience. This pipeline is being progressed. Really clever ideas have been proven in the clinic and are about to start hitting patients arms. Hugely exciting for both cancer patience and share holders.

Lots of company pivot points between now and the mid term to keep the momentum we have seen recently continue.